Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.
Electrofulguration shows long-term efficacy for UTIs in menopausal women
October 11th 2023“These findings demonstrate that electrofulguration provides a durable clinical cure that enables many postmenopausal women to remain UTI-free with minimal to no continued need for antibiotic therapy," says Philippe E. Zimmern, MD.